Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

By L. Rosen, D. Gordon, M. Kaminski, A. Howell, A. Belch, John R. Mackey, J. Apffelstaedt, M. Hussein, R. Coleman, D. Reitsma and 3 more. Cancer Journal, 2001

922 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/c2013f845598789f115fd767a76388d2b1223f7d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. F. Saad
2. R. Coleman
3. A. Lipton
4. L. Rosen
5. A. Stopeck
6. D. Gordon
7. Richard J. Cook
8. Matthew R. Smith

Citations in the corpus

• American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. (2003, background): “In light of the above dose information, a larger phase III randomized trial compared 4 or 8 mg doses of zoledronic acid to 90 mg pamidronate every 3 to 4 weeks in multiple myeloma or breast cancer patients with lytic disease.(4) Due to rises in 4043 ASCO UPDATE ON THE ROLE OF BISPHOSPHONATES”
• Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma (2003, methodology): “The specifications for diagnosing each of these events were described previously.(23) For the primary efficacy analysis, HCM was not included in the definition of SREs, because zoledronic acid already has demonstrated efficacy in treating HCM.”
• Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. (2010, background): “bisphosphonate therapy.(11,12) Nephrotoxicity has been shown to be associated with zoledronic acid therapy and increases with extended treatment.”
• Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. (2003, background): “0).(5) The 8-mg dose of zoledronic acid, however, has been associated with an increased incidence of renal function deterioration, even when administered via 15-minute infusion, and should not be used.”
• Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. (2011, background): “reducing skeletal complications in patients with multiple myeloma or breast cancer and bone metastases in similar degree to pamidronate.(16) Despite appropriate treatment with zoledronic acid, SREs still occur in patients with bone metastases with their attendant morbidity.”
• Bisphosphonates: Mechanism of Action and Role in Clinical Practice (2008, unknown): “…that both pamidronate and zoledronic acid have an important palliative role in reducing the incidence of hypercalcemia and skeletal bone–related events associated with myeloma,93–95 putting IV bisphosphonates at the center of current therapies to prevent and treat myeloma-associated bone disease.”
• Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid (2002, background): “Moreover, ZOL has been shown to be effective in reducing the skeletal complications of bone metastases in patients with breast cancer and osteolytic lesions of multiple myeloma (Rosen et al., 2001).”
• Pathologic fractures correlate with reduced survival in patients with malignant bone disease (2007, background): “The specifications for diagnosing each of these events have been described previously.(7,19,20) Radionuclide bone scans and plain radiographs of”